SLE Treatment

Aug 17, 2026

Summary TYK2 inhibitors are emerging as a major class of oral immunology therapies, aiming to combine biologic-level efficacy with the convenience of a pill and fewer safety concerns than broader JAK inhibitors. Bristol Myers Squibb’s SOTYKTU remains the first approved TYK2 inhibitor and expanded its positio...

Aug 10, 2026

Summary Lupus nephritis treatment is entering a new phase, shifting from broad immunosuppressants to targeted biologics, with BENLYSTA (belimumab) and GAZYVA (obinutuzumab) emerging as key competitors. BENLYSTA is the established benchmark, with over a decade of clinical use in SLE and approvals for lupus ne...

Jul 22, 2026

Summary Systemic lupus erythematosus is a highly unpredictable autoimmune disease characterized by fluctuating flares affecting multiple organs, impacting ~5 million people globally and ~513,000 diagnosed cases in the US (2025), with numbers expected to rise through 2036. Diagnosis is complex and lengthy, of...

Jul 22, 2026

Summary SLE is a chronic autoimmune disease affecting multiple organs, with ~936K diagnosed cases across the 7MM in 2025 and expected growth by 2036. BENLYSTA (belimumab, GSK) remains the cornerstone biologic, targeting BLyS to reduce autoreactive B cells; it expanded into lupus nephritis, pediatrics, and mu...

Jul 21, 2026

Summary Systemic lupus erythematosus, once considered highly unpredictable and difficult to treat, is undergoing a major therapeutic transformation driven by biologics, small molecules, and cell-based therapies. The SLE market is valued at around USD 3 billion in 2025 across the 7MM and is projected to grow ...

May 29, 2026

Systemic lupus erythematosus (SLE) is a chronic autoimmune condition that can affect multiple parts of the body. In 2025, it was estimated that around 512,000 individuals in the United States were living with SLE, as per DelveInsight analysis, with new treatments for SLE urgently needed as 40% of treated SLE patien...